Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Non Operating Income (2018 - 2025)

Northwest Biotherapeutics (NWBO) has 8 years of Non Operating Income data on record, last reported at -$12.5 million in Q3 2025.

  • For Q3 2025, Non Operating Income fell 173.54% year-over-year to -$12.5 million; the TTM value through Sep 2025 reached -$24.9 million, down 289.66%, while the annual FY2024 figure was -$17.3 million, 143.55% down from the prior year.
  • Non Operating Income reached -$12.5 million in Q3 2025 per NWBO's latest filing, down from -$599000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $144.0 million in Q4 2021 and bottomed at -$17.2 million in Q3 2022.
  • Average Non Operating Income over 5 years is $4.5 million, with a median of -$2.3 million recorded in 2024.
  • Peak YoY movement for Non Operating Income: surged 219.92% in 2023, then crashed 934.68% in 2024.
  • A 5-year view of Non Operating Income shows it stood at $144.0 million in 2021, then crashed by 107.03% to -$10.1 million in 2022, then skyrocketed by 111.51% to $1.2 million in 2023, then plummeted by 934.68% to -$9.7 million in 2024, then fell by 28.64% to -$12.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were -$12.5 million in Q3 2025, -$599000.0 in Q2 2025, and -$2.0 million in Q1 2025.